Ge Long Hui A P P·2026-03-03 08:03Core Viewpoint - Company BeiGene is expected to achieve total revenue of $5.3 billion in 2025, representing a year-on-year increase of 40%, and a GAAP net profit of $287 million, marking a turnaround to profitability [1] Financial Performance - The performance aligns with expectations, as the early research pipeline enters a harvest phase [1] - For 2026, the company provides guidance of total revenue between $6.2 billion and $6.4 billion, GAAP operating expenses of $4.7 billion to $4.9 billion, and a gross margin in the high 80% range [1] - GAAP operating profit is projected to be between $700 million and $800 million, while non-GAAP operating profit is expected to be between $1.4 billion and $1.5 billion [1] Product and Pipeline Development - The company's core products are experiencing rapid growth, and the research pipeline is anticipated to see significant catalysts [1] - Due to increased R&D investment, net profit forecasts for 2026 and 2027 have been adjusted to $685 million and $1.08 billion, respectively, down from previous estimates of $795 million and $1.22 billion [1] - A new net profit forecast for 2028 has been introduced at $1.897 billion [1] Market Position and Strategy - The company maintains a solid position as a leader in the domestic biopharma sector, with significant achievements in global expansion [1] - Both commercialization and research are approaching critical inflection points, leading to a maintained "Buy" rating [1]